SummaryEligible participants will receive 10 treatments of radiation therapy to the primary oesophageal cancer, with one treatment given on each working day for 2 weeks. In addition, all participants will receive chemotherapy (including carboplatin and paclitaxel) given intravenously once per week for the same 2 weeks as the radiation therapy. Durvalumab (immunotherapy) will be given intravenously every 4 weeks from the beginning of radiation therapy. After this, participants will continue to receive durvalumab intravenously once every 4 weeks for up to 24 months. If the participants have a metastatic tumour, they will also be given 3 doses of radiation therapy in one week. This radiation therapy will be received 4 weeks after the initial radiation therapy is completed.
It is hoped that this trial can help determine if this chemotherapy with immunotherapy and radiation therapy combination is effective in increasing the ability of the body's immune system to prevent worsening of the cancer and improve swallowing.
Use the hyperlinks, where available to access additional clinical trial information.
Varian Medical Systems, Inc, Australasian Gastro-Intestinal Trials Group (AGITG)
Phase II clinical trial of chemoradioimmunotherapy for the ALleviation of oEsOphageal cancer complications